Findings seen among poor surgical candidates, with recurrence risk of 10 percent seen at 16 months
TUESDAY, March 26, 2024 (HealthDay News) — Cryoablation can be performed effectively in nonsurgical breast cancer patients with varying tumors, according to a study presented at the annual meeting of the Society of Interventional Radiology, held from March 23 to 28 in Salt Lake City.
Jolie Jean, M.D., from Weill Cornell, and Yolanda Bryce, M.D., from the Memorial Sloan Kettering Cancer Center, both in New York City, presented their technique for cryoablation of primary breast cancer (treated from January 2017 to March 2023). The analysis included 60 patients with breast cancer (48 had invasive ductal carcinoma) who were poor surgical candidates or refused surgery.
The researchers found that during a median follow-up of 16 months, there was a recurrence rate of 10 percent (six patients). The risk for recurrence was higher among patients with poorly differentiated disease (risk ratio, 5.5). Invasive lobular carcinoma, estrogen receptor or progesterone receptor, and triple-negative status were not associated with risk. Furthermore, tumor size was similar between the recurrence and nonrecurrence groups (2.53 and 2.54 cm, respectively).
“Surgery is still the best option for tumor removal, but there are thousands of women who, for various reasons, cannot have surgery,” Bryce said in a statement. “We are optimistic that this can give more women hope on their treatment journeys.”
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy
Family History Drives Cancer Risk in BRCA Test Groups
Residential Context Has Larger Impact on Ovarian Cancer Survival in Black Women
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers